

Übersicht der bestätigten und bewerteten Publikationen

Universitätsklinik und Poliklinik für Gynäkologie
Journalbeitrag

Originalarbeit

1. Berndt U., Leplow B., Schoenfeld R., Lantzsch T., Grosse R., Thomssen C.: (2016) Memory and Spatial Cognition in Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy. BREAST CARE, 11: 240-246 [27721710](#)
IF: 1,553; anteiliger IF: 1,16475
2. Busch B., Bley N., Müller S., Glaß M., Misiak D., Lederer M., Vetter M., Strauß H.G., Thomssen C., Hüttelmaier S.: (2016) The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family. NUCLEIC ACIDS RESEARCH, 44: 3845-64 [26917013](#)
IF: 10,162; anteiliger IF: 1,27025
3. Furlanetto J., Eiermann W., Marmé F., Reimer T., Reinisch M., Schmatloch S., Stickeler E., Thomssen C., Untch M., Denkert C., von Minckwitz G., Lederer B., Nekljudova V., Weber K., Loibl S., Möbus V.: (2016) Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study. ANNALS OF ONCOLOGY, 27: 2053-2059 [27502721](#)
IF: 11,855; anteiliger IF: 0,28226
4. Gaß P., Fasching P.A., Fehm T., de Waal J., Rezai M., Baier B., Baake G., Kolberg H.C., Guggenberger M., Warm M., Harbeck N., Wuerstlein R., Deuker J.U., Dall P., Richter B., Wachsmann G., Brucker C., Siebers J.W., Fersis N., Kuhn T., Wolf C., Vollert H.W., Breitbach G.P., Janni W., Landthaler R., Kohls A., Rezek D., Noesselt T., Fischer G., Henschen S., Praetz T., Heyl V., Kühn T., Krauss T., Thomssen C., Hohn A., Tesch H., Mundhenke C., Hein A., Rauh C., Bayer C.M., Jacob A., Schmidt K., Belleville E., Hadji P., Brucker S.Y., Beckmann M.W., Wallwiener D., Kümmel S., Löhberg C.R.: (2016) Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. BREAST CARE, 11: 315-322 [27920623](#)
IF: 1,553; anteiliger IF: 0,01078
5. Gluz O., Liedtke C., Huober J., Peyro-Saint-Paul H., Kates R.E., Kreipe H.H., Hartmann A., Pelz E., Erber R., Mohrmann S., Möbus V., Augustin D., Hoffmann G., Thomssen C., Jänicke F., Kiechle M., Wallwiener D., Kuhn W., Nitz U., Harbeck N., EC-Doc investigators (West German Study Group/AGO-B): (2016) Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. ANNALS OF ONCOLOGY, 27: 1035-40 [27022068](#)
IF: 11,855; anteiliger IF: 0,20798
6. Norbert Nass, Angela Dittmer, Vicky Hellwig, Theresia Lange, Johanna Mirjam Beyer, Benjamin Leyh, Atanas Ignatov, Christine Weißenborn, Tove Kirkegaard, Anne Lykkesfeldt, Thomas Kalinski, Jürgen Dittmer: (2016) Expression of transmembrane protein 26 (TMEM26) in breast cancer and its association with drug response. ONCOTARGET, 7: 38408-38426
IF: 5,168; anteiliger IF: 2,584
7. Schmidt M., Thomssen C., Untch M.: (2016) Intrinsic Subtypes of Primary Breast Cancer - Gene Expression Analysis. Oncology Research and Treatment, 39: 102-10 [27031354](#)
IF: 1,667; anteiliger IF: 0,55567
8. Tempfer C., Horn L.C., Ackermann S., Beckmann M.W., Dittrich R., Einenkel J., Günthert A., Haase H., Kratzsch J., Kreissl M.C., Polterauer S., Ebert A.D., Schneider K.T.M., Strauss H.G., Thiel F.: (2016) Gestational and Non-gestational Trophoblastic Disease. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 032/049, December 2015). GEBURTSHILFE UND FRAUENHEILKUNDE, 76: 134-144 [26941444](#)
IF: 1,07; anteiliger IF: 0,02744
9. Thomssen C., Augustin D., Ettl J., Haidinger R., Lück H.J., Lüftner D., Marmé F., Marschner N., Müller L., Overkamp F., Ruckhäberle E., Thill M., Untch M., Wuerstlein R., Harbeck N.: (2016) ABC3 Consensus: Assessment by a German Group of Experts. BREAST CARE, 11: 61-70 [27051399](#)
IF: 1,553; anteiliger IF: 0,51767
10. Untch M., Augustin D., Ettl J., Haidinger R., Harbeck N., Lück H.J., Lüftner D., Marmé F., Müller L., Overkamp F., Ruckhäberle E., Thill M., Thomssen C., Wuerstlein R., Marschner

N.: (2016) ABC3 Consensus Commented from the Perspective of the German Guidelines: Third International Consensus Conference for Advanced Breast Cancer (ABC3), Lisbon, 07.11.2015. GEBURTSHILFE UND FRAUENHEILKUNDE, 76: 156-163 [26941448](#)

IF: 1,07; anteiliger IF: 0,02744

11. Vogiatzi F., Brandt D.T., Schneikert J., Fuchs J., Grikscheit K., Wanzel M., Pavlakis E., Charles J.P., Timofeev O., Nist A., Mernberger M., Kantelhardt E.J., Siebolts U., Bartel F., Jacob R., Rath A., Moll R., Grosse R., Stiewe T.: (2016) Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 113: E8433-E8442 [27956623](#)

IF: 9,661; anteiliger IF: 0,18943

12. Woelber L., Griebel L.F., Eulenburg C., Sehouli J., Jueckstock J., Hilpert F., de Gregorio N., Hasenburger A., Ignatov A., Hillemanns P., Fuerst S., Strauss H.G., Baumann K.H., Thiel F.C., Mustea A., Meier W., Harter P., Wimberger P., Hanker L.C., Schmalfeldt B., Canzler U., Fehm T., Luyten A., Hellriegel M., Kosse J., Heiss C., Hantschmann P., Mallmann P., Tanner B., Pfisterer J., Richter B., Neuser P., Mahner S.: (2016) Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study. EUROPEAN JOURNAL OF CANCER, 69: 180-188 [27837710](#)

IF: 6,029; anteiliger IF: 0,06483

2016 Summe der Bewertungen: 6,90249, Summe IF = 63.2

Originalarbeit

1. Aapro M., De Laurentiis M., Rea D., Bargallo Rocha J.E., Elizalde R., Landherr L., Linderholm B., Mamounas E., Markopoulos C., Neven P., Petrovsky A., Rouzier R., Smit V., Svedman C., Schneider D., Thomssen C., Martin M.: (2017) The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value? BREAST, 33: 191-199 [28441617](#)

IF: 2,951; anteiliger IF: 0,06558

2. Bernhardt S., Bayerlová M., Vetter M., Wachter A., Mitra D., Hanf V., Lantsch T., Uleer C., Peschel S., John J., Buchmann J., Weigert E., Bürrig K.F., Thomssen C., Korf U., Beissbarth T., Wiemann S., Kantelhardt E.J.: (2017) Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors. BREAST CANCER RESEARCH, 19: 112 [29020998](#)

IF: 6,142; anteiliger IF: 2,30284

3. Cardoso F., Costa A., Senkus E., Aapro M., André F., Barrios C.H., Bergh J., Bhattacharyya G., Biganzoli L., Cardoso M.J., Carey L., Corneliussen-James D., Curigliano G., Dieras V., El Saghir N., Eniu A., Fallowfield L., Fenech D., Francis P., Gelmon K., Gennari A., Harbeck N., Hudis C., Kaufman B., Krop I., Mayer M., Meijer H., Mertz S., Ohno S., Pagani O., Papadopoulos E., Peccatori F., Pernaut-Llorca F., Piccart M.J., Pierga J.Y., Rugo H., Shockney L., Sledge G., Swain S., Thomssen C., Tutt A., Vorobiof D., Xu B., Norton L., Winer E.: (2017) 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). ANNALS OF ONCOLOGY, 28: 16-33 [28177437](#)

IF: 13,926; anteiliger IF: 0,10795

4. Cardoso F., Costa A., Senkus E., Aapro M., André F., Barrios C.H., Bergh J., Bhattacharyya G., Biganzoli L., Cardoso M.J., Carey L., Corneliussen-James D., Curigliano G., Dieras V., El Saghir N., Eniu A., Fallowfield L., Fenech D., Francis P., Gelmon K., Gennari A., Harbeck N., Hudis C., Kaufman B., Krop I., Mayer M., Meijer H., Mertz S., Ohno S., Pagani O., Papadopoulos E., Peccatori F., Pernaut-Llorca F., Piccart M.J., Pierga J.Y., Rugo H., Shockney L., Sledge G., Swain S., Thomssen C., Tutt A., Vorobiof D., Xu B., Norton L., Winer E.: (2017) 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). BREAST, 31: 244-259 [27927580](#)

IF: 2,951; anteiliger IF: 0,02288

5. Dittmer J.: (2017) Mechanisms governing metastatic dormancy in breast cancer. SEMINARS IN CANCER BIOLOGY, 44: 72-82 [28344165](#)

IF: 10,198; anteiliger IF: 10,198

6. Gizaw M., Addissie A., Getachew S., Ayele W., Mitiku I., Moelle U., Yusuf T., Begoihn M., Assefa M., Jemal A., Kantelhardt E.J.: (2017) Cervical cancer patients presentation and survival in the only oncology referral hospital, Ethiopia: a retrospective cohort study. *Infectious Agents and Cancer*, 12: 61 [29213299](#)
IF: 2,123; Anteiliger IF: 0,1571
7. Gnant M., Harbeck N., Thomssen C.: (2017) St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. *BREAST CARE*, 12: 102-107 [28559767](#)
IF: 2,028; Anteiliger IF: 0,676
8. Hack C.C., Fasching P.A., Fehm T., de Waal J., Rezai M., Baier B., Baake G., Kolberg H.C., Guggenberger M., Warm M., Harbeck N., Wuerstlein R., Deuker J.U., Dall P., Richter B., Wachsmann G., Brucker C., Siebers J.W., Fersis N., Kuhn T., Wolf C., Vollert H.W., Breitbach G.P., Janni W., Landthaler R., Kohls A., Rezek D., Noesslet T., Fischer G., Henschen S., Praetz T., Heyl V., Kühn T., Krauss T., Thomssen C., Hohn A., Tesch H., Mundhenke C., Hein A., Rauh C., Bayer C.M., Jacob A., Schmidt K., Belleville E., Hadji P., Brucker S.Y., Wallwiener D., Kümmel S., Beckmann M.W., Paepke D.: (2017) Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. *INTEGRATIVE CANCER THERAPIES*, 16: 165-175 [27627986](#)
IF: 2,657; Anteiliger IF: 0,01845
9. Klapdor R., Hillemanns P., Wölber L., Jückstock J., Hilpert F., de Gregorio N., Iborra S., Sehoul J., Habermann A., Fürst S.T., Strauß H.G., Baumann K., Thiel F., Mustea A., Meier W., Harter P., Wimberger P., Hanker L., Schmalfeldt B., Canzler U., Fehm T., Luyten A., Hellriegel M., Kosse J., Heiss C., Hantschmann P., Mallmann P., Tanner B., Pfisterer J., Richter B., Jäger M., Mahner S.: (2017) Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study. *ANNALS OF SURGICAL ONCOLOGY*, 24: 1314-1321 [27896515](#)
IF: 3,857; Anteiliger IF: 0,04286
10. Liedtke C., Thill M., Jackisch C., Thomssen C., Müller V., Janni W., Janni W., AGO Breast Committee*: (2017) AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2017. *BREAST CARE*, 12: 172-183 [28785186](#)
IF: 2,028; Anteiliger IF: 0,11267
11. Möbus V., von Minckwitz G., Jackisch C., Lück H.J., Schneeweiss A., Tesch H., Elling D., Harbeck N., Conrad B., Fehm T., Huober J., Müller V., Bauerfeind I., du Bois A., Loibl S., Nekljudova V., Untch M., Thomssen C., German Breast Group (GBG) the AGO Breast Study Group (AGO-B) and NOGGO Study Groups: (2017) German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. *ANNALS OF ONCOLOGY*, 28: 1803-1810 [28459941](#)
IF: 13,926; Anteiliger IF: 4,64154
12. Nitz U., Gluz O., Huober J., Kreipe H.H., Kates R.E., Hartmann A., Erber R., Moustafa Z., Scholz M., Lisboa B., Mohrmann S., Möbus V., Augustin D., Hoffmann G., Weiss E., Böhmer S., Kreienberg R., Du Bois A., Sattler D., Thomssen C., Kiechle M., Jänicke F., Wallwiener D., Harbeck N., Kuhn W.: (2017) Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. *ANNALS OF ONCOLOGY*, 28: 2899 [27634692](#)
IF: 13,926; Anteiliger IF: 0,20183
13. Sengal A.T., Haj-Mukhtar N.S., Elhaj A.M., Bedri S., Kantelhardt E.J., Mohamedani A.A.: (2017) Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series. *BMC CANCER*, 17: 804 [29191181](#)
IF: 3,288; Anteiliger IF: 0,274
14. Thomssen C., El Saghir N.S., Francis P.A., Jassem J., Rugo H.S., Untch M.: (2017) Dual HER2 Blockade. *BREAST CARE*, 12: 345-349 [29234257](#)
IF: 2,028; Anteiliger IF: 0,676
15. Trocchi P., Holzhausen H.J., Lönning T., Böcker W., Schmidt-Pokrzywniak A., Thomssen C., Kluttig A., Stang A.: (2017) Intraobserver Agreement on Histopathologic Evaluations of Core Breast Biopsies. *Breast Journal*, 23: 215-219 [27868315](#)
IF: 2,424; Anteiliger IF: 0,13467
16. Untch M., Huober J., Jackisch C., Schneeweiss A., Brucker S.Y., Dall P., Denkert C., Fasching P.A., Fehm T., Gerber B., Janni W., Kühn T., Lüftner D., Möbus V., Müller V., Rody A., Sinn P., Thill M., Thomssen C., Harbeck N., Liedtke C.: (2017) Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference

(Vienna 2017). GEBURTSHILFE UND FRAUENHEILKUNDE, 77: 633-644 [28769126](#)
IF: 1,291; anteiliger IF: 0,02265

17. van Rossum A.G.J., Schouten P.C., Weber K.E., Nekljudova V., Denkert C., Solbach C., Köhne C.H., Thomssen C., Forstbauer H., Hoffmann G., Kohls A., Schmatloch S., Schem C., von Minckwitz G., Karn T., Möbus V.J., Linn S.C., Loibl S., Marmé F.: (2017) BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial. BREAST CANCER RESEARCH AND TREATMENT, 166: 775-785 [28822007](#)
IF: 3,605; anteiliger IF: 0,07069

2017 Summe der Bewertungen: 19,72569, Summe IF = 89.35

Originalarbeit

1. Breunig C., Erdem N., Bott A., Greiwe J.F., Reinz E., Bernhardt S., Giacomelli C., Wachter A., Kantelhardt E.J., Beißbarth T., Vetter M., Wiemann S.: (2018) TGFβ1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer. Molecular Oncology, 12: 1447-1463 [30004628](#)
IF: 5,962; anteiliger IF: 0,39747
2. Cardoso F., Senkus E., Costa A., Papadopoulos E., Aapro M., André F., Harbeck N., Aguilar Lopez B., Barrios C.H., Bergh J., Biganzoli L., Boers-Doets C.B., Cardoso M.J., Carey L.A., Cortés J., Curigliano G., Diéras V., El Saghir N.S., Eniu A., Fallowfield L., Francis P.A., Gelmon K., Johnston S.R.D., Kaufman B., Koppikar S., Krop I.E., Mayer M., Nakigudde G., Offersen B.V., Ohno S., Pagani O., Paluch-Shimon S., Penault-Llorca F., Prat A., Rugo H.S., Sledge G.W., Spence D., Thomssen C., Vorobiof D.A., Xu B., Norton L., Winer E.P.: (2018) 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. ANNALS OF ONCOLOGY, 29: 1634-1657 [30032243](#)
IF: 14,196; anteiliger IF: 0,1183
3. Darlix A., Griguolo G., Thezenas S., Kantelhardt E., Thomssen C., Dieci M.V., Miglietta F., Conte P., Braccini A.L., Ferrero J.M., Bailleux C., Jacot W., Guarneri V.: (2018) Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. JOURNAL OF NEURO-ONCOLOGY, 138: 369-382 [29488184](#)
IF: 3,129; anteiliger IF: 0,18964
4. Dittmer A., Dittmer J.: (2018) Long-term exposure to carcinoma-associated fibroblasts makes breast cancer cells addictive to integrin β1. ONCOTARGET, 9: 22079-22094 [29774124](#)
IF: 4,67; anteiliger IF: 4,67
5. Dittmer J.: (2018) Breast cancer stem cells: Features, key drivers and treatment options. SEMINARS IN CANCER BIOLOGY, 53: 59-74 [30059727](#)
IF: 9,658; anteiliger IF: 9,658
6. Eber-Schulz P., Tariku W., Reibold C., Addissie A., Wickenhauser C., Fathke C., Hauptmann S., Jemal A., Thomssen C., Kantelhardt E.J.: (2018) Survival of breast cancer patients in rural Ethiopia. BREAST CANCER RESEARCH AND TREATMENT, 170: 111-118 [29479644](#)
IF: 3,471; anteiliger IF: 2,60337
7. Gass P., Untch M., Müller V., Möbus V., Thomssen C., Häberle L., Erber R., Hein A., Jud S.M., Lux M.P., Hack C.C., Hartmann A., Kolberg H.C., Ettl J., Lüftner D., Jackisch C., Beckmann M.W., Janni W., Schneeweiss A., Fasching P.A., Nabieva N.: (2018) Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians. GEBURTSHILFE UND FRAUENHEILKUNDE, 78: 707-714 [30057427](#)
IF: 1,312; anteiliger IF: 0,02302
8. Griguolo G., Jacot W., Kantelhardt E., Dieci M.V., Bourgier C., Thomssen C., Bailleux C., Miglietta F., Braccini A.L., Conte P., Ferrero J.M., Guarneri V., Darlix A.: (2018) External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience. BREAST, 37: 36-41 [29073498](#)
IF: 3,494; anteiliger IF: 0,21176
9. Harbeck N., Lüftner D., Marschner N., Untch M., Augustin D., Briest S., Ettl J., Haidinger R., Müller L., Müller V., Ruckhäberle E., Wuerstlein R., Thomssen C.: (2018) ABC4 Consensus:

Assessment by a German Group of Experts. BREAST CARE, 13: 48-58 [29950968](#)

IF: 2,087; anteiliger IF: 0,69567

10. Hartkopf A.D., Huober J., Volz B., Nabieva N., Taran F.A., Schwitulla J., Overkamp F., Kolberg H.C., Hadji P., Tesch H., Häberle L., Ettl J., Lux M.P., Lüftner D., Wallwiener M., Müller V., Beckmann M.W., Belleville E., Wimberger P., Hielscher C., Geberth M., Fersis N., Abenhardt W., Kurbacher C., Wuerstlein R., Thomssen C., Untch M., Fasching P.A., Janni W., Fehm T.N., Wallwiener D., Brucker S.Y., Schneeweiss A.: (2018) Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. BREAST, 37: 42-51 [29100043](#)
IF: 3,494; anteiliger IF: 0,03757
11. Kroeber E.S., Mathewos A., Wondemagegnehu T., Aynalem A., Gemechu T., Piszczan S., Timotewos G., Addissie A., Wienke A., Unverzagt S., Thomssen C., Jemal A., Kantelhardt E.J.: (2018) Vulvar cancer in Ethiopia: A cohort study on the characteristics and survival of 86 patients. MEDICINE, 97: e0041 [29489654](#)
IF: 1,87; anteiliger IF: 0,73666
12. Möbus V., Jackisch C., Lueck H.J., du Bois A., Thomssen C., Kuhn W., Nitz U., Schneeweiss A., Huober J., Harbeck N., von Minckwitz G., Runnebaum I.B., Hinke A., Konecny G.E., Untch M., Kurbacher C., AGO Breast Study Group (AGO-B), Kahlert S., Hauser N., Marmé F., Kiesel L., Wallwiener D., Rautenberg B., Hofmann R., Barinoff J., Stickeler E., Eidtmann H., Müller V., Emons G., Mallmann P., Hackenberg R., Hielscher C., Räber G., Sommer H., Schmidt-Rhode P., Jahns B., von der Assen A., Dietterle S., Kaufmann M., Strunk C., Goebel R., Paepke S., Paulenz A., Junker-Stein A., Rhein U., Bremer K., Bauer W., Hohlweg-Majert P., Kramer D., Meerpohl H.G., Diedrich K., Dall P., Kölbl H., Brückner B., Gros R., Stehle H., Lobodasch K., Dinkelacker T., Klöpffer E., Karg C., Stibora M., Weise W., Melchert F., Mohrmann S., Klatt C., Schmidt M., Glados M., Mickan H., Pollmanns A., Beck T., Schröder W., Klingemann H., Köhler G., Freier W., Graßhoff S.T., Söling U., Keil E., Höß C., Kullmer U., Niesel A., Bodenstein H., Bartzke G., Schlotter C.M., Wiest W., Ernst W., Brudler O., Heinrich B., Hackmann J., Niedner W., Hoffmann G., Knapp W., Dresemann G., Karl C., Klemm F.J., Schliesser G.C., Butterwegge M., Meden H., Kirschbaum M., Schwenzer T., Voigt H.J., Weiß U., Önder G., Langer W., Glaubitz M., Beha M., Coumbos A., Ko Y., Deuker J.U., Prümmer O., Wagner U., Kohlstedt A., Schreiber P., Jovanovic V., Drzewiecki K., Guba H., Seipt H., Stauch M., Maintz C., Morenz B.: (2018) Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. ANNALS OF ONCOLOGY, 29: 178-185 [29069370](#)
IF: 14,196; anteiliger IF: 0,04044
13. Moelle U., Mathewos A., Aynalem A., Wondemagegnehu T., Yonas B., Begoihn M., Addissie A., Unverzagt S., Jemal A., Thomssen C., Vordermark D., Kantelhardt E.J.: (2018) Cervical Cancer in Ethiopia: The Effect of Adherence to Radiotherapy on Survival. ONCOLOGIST, 23: 1024-1032 [29567823](#)
IF: 5,252; anteiliger IF: 3,85094
14. Nabieva N., Fehm T., Häberle L., de Waal J., Rezai M., Baier B., Baake G., Kolberg H.C., Guggenberger M., Warm M., Harbeck N., Wuerstlein R., Deuker J.U., Dall P., Richter B., Wachsmann G., Brucker C., Siebers J.W., Popovic M., Kuhn T., Wolf C., Vollert H.W., Breitbach G.P., Janni W., Landthaler R., Kohls A., Rezek D., Noesselt T., Fischer G., Henschen S., Praetz T., Heyl V., Kühn T., Krauss T., Thomssen C., Hohn A., Tesch H., Mundhenke C., Hein A., Hack C.C., Schmidt K., Belleville E., Brucker S.Y., Kümmel S., Beckmann M.W., Wallwiener D., Hadji P., Fasching P.A.: (2018) Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. EUROPEAN JOURNAL OF CANCER, 96: 82-90 [29679775](#)
IF: 6,68; anteiliger IF: 0,04841
15. Nabieva N., Kellner S., Fehm T., Häberle L., de Waal J., Rezai M., Baier B., Baake G., Kolberg H.C., Guggenberger M., Warm M., Harbeck N., Wuerstlein R., Deuker J.U., Dall P., Richter B., Wachsmann G., Brucker C., Siebers J.W., Fersis N., Kuhn T., Wolf C., Vollert H.W., Breitbach G.P., Janni W., Landthaler R., Kohls A., Rezek D., Noesselt T., Fischer G., Henschen S., Praetz T., Heyl V., Kühn T., Krauss T., Thomssen C., Hohn A., Tesch H., Mundhenke C., Hein A., Rauh C., Bayer C.M., Jacob A., Schmidt K., Belleville E., Brucker S.Y., Kümmel S., Beckmann M.W., Wallwiener D., Hadji P., Fasching P.A.: (2018) Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM

study with 3941 patients. ANNALS OF ONCOLOGY, 29: 186-192 [29045642](#)

IF: 14,196; anteiliger IF: 0,09657

16. Schmitt M., Wilhelm O.G., Noske A., Schricker G., Napieralski R., Vetter M., Aubele M., Perkins J., Lauber J., Ulm K., Thomssen C., Martens J.W.M., Weichert W., Kiechle M.: (2018) DNA Methylation to Predict Outcome in High-Risk Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy. BREAST CARE, 13: 425-433 [30800037](#)
IF: 2,087; anteiliger IF: 0,11594
17. Shiferaw S., Addissie A., Gizaw M., Hirpa S., Ayele W., Getachew S., Kantelhardt E.J., Assefa M., Jemal A.: (2018) Knowledge about cervical cancer and barriers toward cervical cancer screening among HIV-positive women attending public health centers in Addis Ababa city, Ethiopia. Cancer Medicine, 7: 903-912 [29441700](#)
IF: 3,357; anteiliger IF: 0,15986
18. Timotewos G., Solomon A., Mathewos A., Addissie A., Bogale S., Wondemagegnehu T., Aynalem A., Ayalnesh B., Dagnechew H., Bireda W., Kroeber E.S., Mikolajczyk R., Bray F., Jemal A., Kantelhardt E.J.: (2018) First data from a population based cancer registry in Ethiopia. Cancer Epidemiology, 53: 93-98 [29414637](#)
IF: 2,619; anteiliger IF: 0,873
19. Untch M., Würstlein R., Marschner N., Lüftner D., Augustin D., Briest S., Ettl J., Haidinger R., Müller L., Müller V., Ruckhäberle E., Harbeck N., Thomssen C.: (2018) 4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts. GEBURTSHILFE UND FRAUENHEILKUNDE, 78: 469-480 [29880982](#)
IF: 1,312; anteiliger IF: 0,43733
20. Weiner C.M., Mathewos A., Addissie A., Ayele W., Aynalem A., Wondemagegnehu T., Wienke A., Jemal A., Zerche P., Thomssen C., Seidler A., Kantelhardt E.J.: (2018) Characteristics and follow-up of metastatic breast cancer in Ethiopia: A cohort study of 573 women. BREAST, 42: 23-30 [30149234](#)
IF: 3,494; anteiliger IF: 1,28102
21. Wöckel A., Festl J., Stüber T., Brust K., Krockenberger M., Heuschmann P.U., Jírů-Hillmann S., Albert U.S., Budach W., Follmann M., Janni W., Kopp I., Kreienberg R., Kühn T., Langer T., Nothacker M., Scharl A., Schreer I., Link H., Engel J., Fehm T., Weis J., Welt A., Steckelberg A., Feyer P., König K., Hahne A., Baumgartner T., Kreipe H.H., Knoefel W.T., Denking M., Brucker S., Lüftner D., Kubisch C., Gerlach C., Lebeau A., Siedentopf F., Petersen C., Bartsch H.H., Schulz-Wendtland R., Hahn M., Hanf V., Müller-Schimpfle M., Henschler U., Roncarati R., Katalinic A., Heitmann C., Honegger C., Paradies K., Bjelic-Radisic V., Degenhardt F., Wenz F., Rick O., Hölzel D., Zaiss M., Kemper G., Budach V., Denkert C., Gerber B., Tesch H., Hirsmüller S., Sinn H.P., Dunst J., Münstedt K., Bick U., Fallenberg E., Tholen R., Hung R., Baumann F., Beckmann M.W., Blohmer J., Fasching P., Lux M.P., Harbeck N., Hadji P., Hauner H., Heywang-Köbrunner S., Huober J., Hübner J., Jackisch C., Loibl S., Lück H.J., von Minckwitz G., Möbus V., Müller V., Nöthlings U., Schmidt M., Schmutzler R., Schneeweiss A., Schütz F., Stickeler E., Thomssen C., Untch M., Wesselmann S., Bücken A., Buck A., Stangl S.: (2018) Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. GEBURTSHILFE UND FRAUENHEILKUNDE, 78: 1056-1088 [30581198](#)
IF: 1,312; anteiliger IF: 0,0046
22. Wöckel A., Festl J., Stüber T., Brust K., Stangl S., Heuschmann P.U., Albert U.S., Budach W., Follmann M., Janni W., Kopp I., Kreienberg R., Kühn T., Langer T., Nothacker M., Scharl A., Schreer I., Link H., Engel J., Fehm T., Weis J., Welt A., Steckelberg A., Feyer P., König K., Hahne A., Kreipe H.H., Knoefel W.T., Denking M., Brucker S., Lüftner D., Kubisch C., Gerlach C., Lebeau A., Siedentopf F., Petersen C., Bartsch H.H., Schulz-Wendtland R., Hahn M., Hanf V., Müller-Schimpfle M., Henschler U., Roncarati R., Katalinic A., Heitmann C., Honegger C., Paradies K., Bjelic-Radisic V., Degenhardt F., Wenz F., Rick O., Hölzel D., Zaiss M., Kemper G., Budach V., Denkert C., Gerber B., Tesch H., Hirsmüller S., Sinn H.P., Dunst J., Münstedt K., Bick U., Fallenberg E., Tholen R., Hung R., Baumann F., Beckmann M.W., Blohmer J., Fasching P.A., Lux M.P., Harbeck N., Hadji P., Hauner H., Heywang-Köbrunner S., Huober J., Hübner J., Jackisch C., Loibl S., Lück H.J., von Minckwitz G., Möbus V., Müller V., Nöthlings U., Schmidt M., Schmutzler R., Schneeweiss A., Schütz F., Stickeler E., Thomssen C., Untch M., Wesselmann S., Bücken A., Krockenberger M.: (2018) Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) -

Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. GEBURTSHILFE UND FRAUENHEILKUNDE, 78: 927-948 [30369626](#)

IF: 1,312; anteiliger IF: 0,00472

23. Woldetensay Y.K., Belachew T., Biesalski H.K., Ghosh S., Lacruz M.E., Scherbaum V., Kantelhardt E.J.: (2018) The role of nutrition, intimate partner violence and social support in prenatal depressive symptoms in rural Ethiopia: community based birth cohort study. BMC Pregnancy and Childbirth, 18: 374 [30219050](#)
IF: 2,413; anteiliger IF: 0,80433
24. Woldetensay Y.K., Belachew T., Tesfaye M., Spielman K., Biesalski H.K., Kantelhardt E.J., Scherbaum V.: (2018) Validation of the Patient Health Questionnaire (PHQ-9) as a screening tool for depression in pregnant women: Afaan Oromo version. PLoS One, 13: e0191782 [29408928](#)
IF: 2,776; anteiliger IF: 0,18507

2018 Summe der Bewertungen: 27,24368, Summe IF = 114.35

Originalarbeit

1. Balic M., Thomssen C., Würstlein R., Gnant M., Harbeck N.: (2019) St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. BREAST CARE, 14: 103-110 [31798382](#)
IF: 2,029; anteiliger IF: 0,22544
2. Bauer M., Kantelhardt E.J., Stiewe T., Nist A., Mernberger M., Politt K., Hanf V., Lantsch T., Uleer C., Peschel S., John J., Buchmann J., Weigert E., Bürrig K.F., Wickenhauser C., Thomssen C., Bartel F., Vetter M.: (2019) Specific Allelic Variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients. ONCOTARGET, 10: 1975-1992 [30956778](#)
IF: 4,67; anteiliger IF: 1,02133
3. Begoihn M., Mathewos A., Aynalem A., Wondemagegnehu T., Moelle U., Gizaw M., Wienke A., Thomssen C., Worku D., Addissie A., Jemal A., Kantelhardt E.J.: (2019) Cervical cancer in Ethiopia - predictors of advanced stage and prolonged time to diagnosis. Infectious Agents and Cancer, 14: 36 [31737087](#)
IF: 2,74; anteiliger IF: 2,00906
4. Berchtold E., Vetter M., Gündert M., Csaba G., Fathke C., Ulbrich S.E., Thomssen C., Zimmer R., Kantelhardt E.J.: (2019) Comparison of six breast cancer classifiers using qPCR. BIOINFORMATICS, 35: 3412-3420 [30759193](#)
IF: 5,61; anteiliger IF: 2,4041
5. Denschlag D., Ackermann S., Battista M.J., Cremer W., Egerer G., Follmann M., Haas H., Harter P., Hettmer S., Horn L.C., Juhasz-Boess I., Kast K., Köhler G., Kröncke T., Lindel K., Mallmann P., Meyer-Steinacker R., Mustea A., Petru E., Reichardt P., Schmidt D., Strauss H.G., Tempfer C., Thiel F., Ulrich U., Vogl T., Vordermark D., Gass P., Beckmann M.W.: (2019) Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019). GEBURTSHILFE UND FRAUENHEILKUNDE, 79: 1043-1060 [31656317](#)
IF: 2,382; anteiliger IF: 0,02941
6. Ditsch N., Untch M., Thill M., Müller V., Janni W., Albert U.S., Bauerfeind I., Blohmer J., Budach W., Dall P., Diel I., Fasching P.A., Fehm T., Friedrich M., Gerber B., Hanf V., Harbeck N., Huober J., Jackisch C., Kolberg-Liedtke C., Kreipe H.H., Krug D., Kühn T., Kümmel S., Loibl S., Lüftner D., Lux M.P., Maass N., Möbus V., Müller-Schimpfle M., Mundhenke C., Nitz U., Rhiem K., Rody A., Schmidt M., Schneeweiss A., Schütz F., Sinn H.P., Solbach C., Solomayer E.F., Stickeler E., Thomssen C., Wenz F., Witzel I., Wöckel A.: (2019) AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. BREAST CARE, 14: 224-245 [31558897](#)
IF: 2,029; anteiliger IF: 0,01583
7. Feuchtner J., Mathewos A., Solomon A., Timotewos G., Aynalem A., Wondemagegnehu T., Gebremedhin A., Adugna F., Griesel M., Wienke A., Addissie A., Jemal A., Kantelhardt E.J.: (2019) Addis Ababa population-based pattern of cancer therapy, Ethiopia. PLoS One,

- 14: e0219519 [31536505](#)
IF: 2,74; anteiliger IF: 0,91324
8. Furlanetto J., von Minckwitz G., Lederer B., Möbus V., Schneeweiss A., Huober J., Fasching P.A., Gerber B., Bauerfeind I., Nitz U., Lück H.J., Hanusch C., Thomssen C., Untch M., Nekljudova V., Mehta K., Loibl S.: (2019) Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. *Breast Cancer*, 26: 826-834 [31254201](#)
IF: 2,695; anteiliger IF: 0,05983
 9. Gebremariam A., Addissie A., Worku A., Assefa M., Kantelhardt E.J., Jemal A.: (2019) Perspectives of patients, family members, and health care providers on late diagnosis of breast cancer in Ethiopia: A qualitative study. *PLoS One*, 14: e0220769 [31369640](#)
IF: 2,74; anteiliger IF: 0,22824
 10. Gebremariam A., Addissie A., Worku A., Assefa M., Pace L.E., Kantelhardt E.J., Jemal A.: (2019) Time intervals experienced between first symptom recognition and pathologic diagnosis of breast cancer in Addis Ababa, Ethiopia: a cross-sectional study. *BMJ OPEN*, 9: e032228 [31719089](#)
IF: 2,496; anteiliger IF: 0,16648
 11. Gebremariam A., Addissie A., Worku A., Hirpa S., Assefa M., Pace L.E., Kantelhardt E.J., Jemal A.: (2019) Breast and cervical cancer patients' experience in Addis Ababa city, Ethiopia: a follow-up study protocol. *BMJ OPEN*, 9: e027034 [30967409](#)
IF: 2,496; anteiliger IF: 0,13878
 12. Getachew S., Getachew E., Gizaw M., Ayele W., Addissie A., Kantelhardt E.J.: (2019) Cervical cancer screening knowledge and barriers among women in Addis Ababa, Ethiopia. *PLoS One*, 14: e0216522 [31075122](#)
IF: 2,74; anteiliger IF: 0,91324
 13. Gizaw M., Teka B., Ruddies F., Abebe T., Kaufmann A.M., Worku A., Wienke A., Jemal A., Addissie A., Kantelhardt E.J.: (2019) Uptake of Cervical Cancer Screening in Ethiopia by Self-Sampling HPV DNA Compared to Visual Inspection with Acetic Acid: A Cluster Randomized Trial. *Cancer Prevention Research*, 12: 609-616 [31337647](#)
IF: 3,473; anteiliger IF: 1,15755
 14. Huober J., Bartsch R., Marmé F., Pagani O., Thomssen C.: (2019) Luminal Metastatic Breast Cancer. *BREAST CARE*, 14: 99-101 [31798381](#)
IF: 2,029; anteiliger IF: 0,67633
 15. Kuhlmann J.D., Bachmann H.S., Link T., Wimberger P., Kröber E., Thomssen C., Mallé B., Bethmann D., Vetter M., Kantelhardt E.J.: (2019) Association of caspase 8 polymorphisms - 652 6N InsDel and Asp302His with progression-free survival and tumor infiltrating lymphocytes in early breast cancer. *Scientific Reports*, 9: 12594 [31467295](#)
IF: 3,998; anteiliger IF: 1,83268
 16. Lüftner D., Bauerfeind I., Braun M., Brucker S.Y., Fasching P.A., Felberbaum R., Hagemann F., Haidinger R., Harbeck N., Hönig A., Huober J., Jackisch C., Kolberg H.C., Kolberg-Liedtke C., Kühn T., Maass N., Reimer T., Schneeweiss A., Schumacher-Wulf E., Schütz F., Thomssen C., Untch M., Wuerstlein R., Thill M.: (2019) Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). *BREAST CARE*, 14: 315-324 [31798392](#)
IF: 2,029; anteiliger IF: 0,03074
 17. Nabieva N., Häberle L., Brucker S.Y., Janni W., Volz B., Loehberg C.R., Hartkopf A.D., Walter C.B., Baake G., Fridman A., Malter W., Wuerstlein R., Harbeck N., Hoffmann O., Kuemmel S., Martin B., Thomssen C., Graf H., Wolf C., Lux M.P., Bayer C.M., Rauh C., Hack C.C., Almstedt K., Gass P., Heindl F., Brodkorb T., Lindner C., Kolberg H.C., Krabisch P., Weigel M., Steinfeld-Birg D., Kohls A., Brucker C., Schulz V., Fischer G., Pelzer V., Rack B., Beckmann M.W., Fehm T., Rody A., Maass N., Hein A., Fasching P.A.: (2019) Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. *INTERNATIONAL JOURNAL OF CANCER*, 145: 2114-2121 [30901076](#)
IF: 5,145; anteiliger IF: 0,04065
 18. Piszczan S., Desalegn D., Petros H., Gurmu M., Kroeber E.S., Addissie A., Mikolajczyk R., Ghebre R.G., Mathewos A., Thomssen C., Jemal A., Kantelhardt E.J.: (2019) Clinical Characteristics and Survival of Patients with Malignant Ovarian Tumors in Addis Ababa, Ethiopia. *ONCOLOGIST*, 24: e303-e311 [31023861](#)
IF: 5,025; anteiliger IF: 3,517
 19. Sung H., DeSantis C.E., Fedewa S.A., Kantelhardt E.J., Jemal A.: (2019) Breast cancer subtypes among Eastern-African-born black women and other black women in the United

States. CANCER, 125: 3401-3411 [31190337](#)

IF: 5,742; anteiliger IF: 0,63794

20. Thill M., Jackisch C., Janni W., Müller V., Albert U.S., Bauerfeind I., Blohmer J., Budach W., Dall P., Diel I., Fasching P.A., Fehm T., Friedrich M., Gerber B., Hanf V., Harbeck N., Huober J., Kolberg-Liedtke C., Kreipe H.H., Krug D., Kühn T., Kümmel S., Loibl S., Lüftner D., Lux M.P., Maass N., Möbus V., Müller-Schimpfle M., Mundhenke C., Nitz U., Rhiem K., Rody A., Schmidt M., Schneeweiss A., Schütz F., Sinn H.P., Solbach C., Solomayer E.F., Stickeler E., Thomssen C., Untch M., Wenz F., Witzel I., Wöckel A., Ditsch N.: (2019) AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. BREAST CARE, 14: 247-255 [31558898](#)
IF: 2,029; anteiliger IF: 0,01583
21. Untch M., Thomssen C., Bauerfeind I., Braun M., Brucker S.Y., Felberbaum R., Hagemann F., Haidinger R., Hönl A., Huober J., Jackisch C., Kolberg H.C., Kolberg-Liedtke C., Kühn T., Lüftner D., Maass N., Reimer T., Schneeweiss A., Schumacher-Wulf E., Schütz F., Thill M., Wuerstlein R., Fasching P.A., Harbeck N.: (2019) Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). GEBURTSHILFE UND FRAUENHEILKUNDE, 79: 591-604 [31217628](#)
IF: 2,382; anteiliger IF: 0,03621
22. von Minckwitz G., Huang C.S., Mano M.S., Loibl S., Mamounas E.P., Untch M., Wolmark N., Rastogi P., Schneeweiss A., Redondo A., Fischer H.H., Jacot W., Conlin A.K., Arce-Salinas C., Wapnir I.L., Jackisch C., DiGiovanna M.P., Fasching P.A., Crown J.P., Wülfing P., Shao Z., Rota Caremoli E., Wu H., Lam L.H., Tesarowski D., Smitt M., Douthwaite H., Singel S.M., Geyer C.E., KATHERINE Investigators: (2019) Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 380: 617-628 [30516102](#)
IF: 74,699; anteiliger IF: 0,08217
23. Wallwiener M., Nabieva N., Feisst M., Fehm T., de Waal J., Rezai M., Baier B., Baake G., Kolberg H.C., Guggenberger M., Warm M., Harbeck N., Wuerstlein R., Deuker J.U., Dall P., Richter B., Wachsmann G., Brucker C., Siebers J.W., Popovic M., Kuhn T., Wolf C., Vollert H.W., Breitbach G.P., Janni W., Landthaler R., Kohls A., Rezek D., Noesselt T., Fischer G., Henschen S., Praetz T., Heyl V., Kühn T., Krauss T., Thomssen C., Hohn A., Tesch H., Mundhenke C., Hein A., Rauh C., Bayer C.M., Schmidt K., Belleville E., Brucker S.Y., Hadji P., Beckmann M.W., Wallwiener D., Kümmel S., Hartkopf A., Fasching P.A.: (2019) Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. BMC CANCER, 19: 611 [31227025](#)
IF: 3,15; anteiliger IF: 0,02142
24. Wunderle M., Pretscher J., Brucker S.Y., Volz B., Hartmann A., Fiessler C., Hein A., Häberle L., Jud S.M., Lux M.P., Janni W., Loehberg C.R., Hartkopf A.D., Walter C.B., Baake G., Fridman A., Malter W., Wuerstlein R., Harbeck N., Hoffmann O., Kümmel S., Martin B., Thomssen C., Graf H., Wolf C., Bayer C.M., Hack C.C., Almstedt K., Gass P., Heindl F., Brodkorb T.F., Nabieva N., Lindner C., Kolberg H.C., Krabisch P., Weigel M., Steinfeld-Birg D., Kohls A., Brucker C., Schulz V., Fischer G., Pelzer V., Wallwiener D., Rack B., Fehm T., Rody A., Maass N., Beckmann M.W., Fasching P.A., Rauh C.: (2019) Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 174: 453-461 [30603996](#)
IF: 3,831; anteiliger IF: 0,0266

2019 Summe der Bewertungen: 16,2001, Summe IF = 148.9

Originalarbeit

1. Abera S.F., Kantelhardt E.J., Bezabih A.M., Tsadik M., Lauvai J., Ejeta G., Wienke A., Frank J., Scherbaum V.: (2020) What factors are associated with maternal undernutrition in eastern zone of Tigray, Ethiopia? Evidence for nutritional well-being of lactating mothers. BMC

PUBLIC HEALTH, 20: 1214 [32770979](#)

IF: 2,52; anteiliger IF: 0,11995

2. Bley N., Schott A., Müller S., Misiak D., Lederer M., Fuchs T., Aßmann C., Glaß M., Ihling C., Sinz A., Pazaitis N., Wickenhauser C., Vetter M., Ungurs O., Strauss H.G., Thomssen C., Hüttelmaier S.: (2020) IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer. RNA Biology, Epub: 1-13 [32876513](#)
IF: 5,35; anteiliger IF: 0,35631
3. Cardoso F., Paluch-Shimon S., Senkus E., Curigliano G., Aapro M.S., André F., Barrios C.H., Bergh J., Bhattacharyya G.S., Biganzoli L., Boyle F., Cardoso M.J., Carey L.A., Cortés J., El Saghir N.S., Elzayat M., Eniu A., Fallowfield L., Francis P.A., Gelmon K., Gligorov J., Haidinger R., Harbeck N., Hu X., Kaufman B., Kaur R., Kiely B.E., Kim S.B., Lin N.U., Mertz S.A., Neciosup S., Offersen B.V., Ohno S., Pagani O., Prat A., Penault-Llorca F., Rugo H.S., Sledge G.W., Thomssen C., Vorobiof D.A., Wiseman T., Xu B., Norton L., Costa A., Winer E.P.: (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). ANNALS OF ONCOLOGY, Epub: v [32979513](#)
IF: 18,274; anteiliger IF: 0,14254
4. Dereje N., Gebremariam A., Addissie A., Worku A., Assefa M., Abraha A., Tigeneh W., Kantelhardt E.J., Jemal A.: (2020) Factors associated with advanced stage at diagnosis of cervical cancer in Addis Ababa, Ethiopia: a population-based study. BMJ OPEN, 10: e040645 [33051237](#)
IF: 2,496; anteiliger IF: 0,11881
5. Ditsch N., Untch M., Kolberg-Liedtke C., Jackisch C., Krug D., Friedrich M., Janni W., Müller V., Albert U.S., Banys-Paluchowski M., Bauerfeind I., Blohmer J.U., Budach W., Dall P., Diel I., Fallenberg E.M., Fasching P.A., Fehm T., Gerber B., Gluz O., Hanf V., Harbeck N., Heil J., Hooper J., Kreipe H.H., Kühn T., Kümmel S., Loibl S., Lüftner D., Lux M., Maass N., Moebus V., Mundhenke C., Park-Simon T.W., Reimer T., Rhiem K., Rody A., Schmidt M., Schneeweiss A., Solbach C., Solomayer E.F., Stickeler E., Thomssen C., Witzel I., Wöckel A., Thill M.: (2020) AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. BREAST CARE, 15: 294-309 [32774225](#)
IF: 2,029; anteiliger IF: 0,01542
6. Dittmer A., Dittmer J.: (2020) Carcinoma-Associated Fibroblasts Promote Growth of Sox2-Expressing Breast Cancer Cells. Cancers, 12: xx [33228022](#)
IF: 6,13; anteiliger IF: 6,13
7. Dittmer A., Lange T., Leyh B., Dittmer J.: (2020) Protein- and growth-modulatory effects of carcinoma-associated fibroblasts on breast cancer cells: Role of interleukin-6. INTERNATIONAL JOURNAL OF ONCOLOGY, 56: 258-272 [31789400](#)
IF: 3,899; anteiliger IF: 3,89926
8. Gebremariam A., Dereje N., Addissie A., Worku A., Assefa M., Abreha A., Tigeneh W., Pace L.E., Kantelhardt E.J., Jemal A.: (2020) Factors associated with late-stage diagnosis of breast cancer among women in Addis Ababa, Ethiopia. BREAST CANCER RESEARCH AND TREATMENT, Epub: Epub [32948993](#)
IF: 3,831; anteiliger IF: 0,15975
9. Getachew S., Tesfaw A., Kaba M., Wienke A., Taylor L., Kantelhardt E.J., Addissie A.: (2020) Perceived barriers to early diagnosis of breast Cancer in south and southwestern Ethiopia: a qualitative study. BMC WOMENS HEALTH, 20: 38 [32103774](#)
IF: 1,54; anteiliger IF: 0,10272
10. Hack C.C., Häberle L., Brucker S.Y., Janni W., Volz B., Loehberg C.R., Hartkopf A.D., Walter C.B., Baake G., Fridman A., Malter W., Wuerstlein R., Harbeck N., Hoffmann O., Kuemmel S., Martin B., Thomssen C., Graf H., Wolf C., Lux M.P., Bayer C.M., Rauh C., Almstedt K., Gass P., Heindl F., Brodkorb T., Willer L., Lindner C., Kolberg H.C., Krabisch P., Weigel M., Steinfeld-Birg D., Kohls A., Brucker C., Schulz V., Fischer G., Pelzer V., Rack B., Beckmann M.W., Fehm T., Rody A., Maass N., Hein A., Fasching P.A., Nabieva N.: (2020) Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. BREAST, 50: 11-18 [31958661](#)
IF: 3,754; anteiliger IF: 0,0291
11. Harbeck N., Thomssen C., Gnant M.: (2020) Virtual Science in Senology: Let Us Not Throw out the Baby with the Bathwater. BREAST CARE, 15: 323-324 [32982640](#)
IF: 2,029; anteiliger IF: 0,67627

12. Joko-Fru W.Y., Miranda-Filho A., Soerjomataram I., Egue M., Akele-Akpo M.T., N'da G., Assefa M., Buziba N., Korir A., Kamate B., Traore C., Manraj S., Lorenzoni C., Carrilho C., Hansen R., Finesse A., Somdyala N., Wabinga H., Chingonzoh T., Borok M., Chokunonga E., Liu B., Kantelhardt E., McGale P., Parkin D.M.: (2020) Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis and human development index: A population-based registry study. INTERNATIONAL JOURNAL OF CANCER, 146: 1208-1218 [31087650](#)
IF: 5,145; anteiliger IF: 0,0746
13. Kantelhardt E.J., Assefa M., McCormack V., Cubasch H., Jemal A., Pace L.E.: (2020) Expert Discussion: Breast Cancer in Low-Resource Countries. BREAST CARE, 15: 310-313 [32774226](#)
IF: 2,029; anteiliger IF: 0,67627
14. Mezger N.C.S., Feuchtner J., Griesel M., Hämmerl L., Seraphin T.P., Zietsman A., Péko J.F., Tadesse F., Buziba N.G., Wabinga H., Nyanchama M., Borok M.Z., Kéita M., N'da G., Lorenzoni C.F., Akele-Akpo M.T., Gottschick C., Binder M., Mezger J., Jemal A., Parkin D.M., Wickenhauser C., Kantelhardt E.J.: (2020) Clinical presentation and diagnosis of adult patients with non-Hodgkin lymphoma in Sub-Saharan Africa. BRITISH JOURNAL OF HAEMATOLOGY, 190: 209-221 [32181503](#)
IF: 5,518; anteiliger IF: 1,83915
15. Ortmann O., Torode J., Schmiegel W., Thomssen C., Hakama M., Basu P., Ringborg U., Helbig U., participants of the ERTM: (2020) Knowledge transfer as a tool towards improvement of cancer care in low- and middle-income countries. 6th European Roundtable Meeting (ERTM), June 14th, 2019, Berlin, Germany. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 146: 1813-1818 [32270287](#)
IF: 3,656; anteiliger IF: 0,17403
16. Parkin D.M., Hämmerl L., Ferlay J., Kantelhardt E.J.: (2020) Cancer in Africa 2018: The role of infections. INTERNATIONAL JOURNAL OF CANCER, 146: 2089-2103 [31254479](#)
IF: 5,145; anteiliger IF: 1,71483
17. Ruddies F., Gizaw M., Teka B., Thies S., Wienke A., Kaufmann A.M., Abebe T., Addissie A., Kantelhardt E.J.: (2020) Cervical cancer screening in rural Ethiopia: a cross-sectional knowledge, attitude and practice study. BMC CANCER, 20: 563 [32552740](#)
IF: 3,15; anteiliger IF: 1,0499
18. Schmid P., Cortes J., Pusztai L., McArthur H., Kümmel S., Bergh J., Denkert C., Park Y.H., Hui R., Harbeck N., Takahashi M., Foukakis T., Fasching P.A., Cardoso F., Untch M., Jia L., Karantza V., Zhao J., Aktan G., Dent R., O'Shaughnessy J., KEYNOTE-522 Investigators: (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 382: 810-821 [32101663](#)
IF: 74,699; anteiliger IF: 0,24651
19. Schneeweiss A., Ettl J., Lüftner D., Beckmann M.W., Belleville E., Fasching P.A., Fehm T.N., Geberth M., Häberle L., Hadji P., Hartkopf A.D., Hielscher C., Huober J., Ruckhäberle E., Janni W., Kolberg H.C., Kurbacher C.M., Klein E., Lux M.P., Müller V., Nabieva N., Overkamp F., Tesch H., Laakmann E., Taran F.A., Seitz J., Thomssen C., Untch M., Wimberger P., Wuerstlein R., Volz B., Wallwiener D., Wallwiener M., Brucker S.Y.: (2020) Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. BREAST, 54: 88-95 [32956934](#)
IF: 3,754; anteiliger IF: 0,03904
20. Seliger G., Krol I., Worlitzsch D., Kantelhardt E.J., Moritz S., Tchirikov M.: (2020) [Reduction of Visitor- and Staff-Associated Risk of Infection by Complex Intervention in the Department of Feto-Maternal Medicine]. ZEITSCHRIFT FÜR GEBURTSHILFE UND NEONATOLOGIE, 224: 297-305 [32906163](#)
IF: 0,667; anteiliger IF: 0,05556
21. Sengayi-Muchengeti M., Joko-Fru W.Y., Miranda-Filho A., Egue M., Akele-Akpo M.T., N'da G., Mathewos A., Buziba N., Korir A., Manraj S., Lorenzoni C., Carrilho C., Hansen R., Finesse A., Somdyala N.I.M., Wabinga H., Chingonzoh T., Borok M., Chokunonga E., Liu B., Singh E., Kantelhardt E.J., Parkin D.M.: (2020) Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: A population-based registry study. INTERNATIONAL JOURNAL OF CANCER, 147: 3037-3048 [32449157](#)
IF: 5,145; anteiliger IF: 0,08181
22. Seraphin T.P., Joko-Fru W.Y., Kamaté B., Chokunonga E., Wabinga H., Somdyala N.I.M., Manraj S.S., Ogunbiyi O.J., Dzamalala C.P., Finesse A., Korir A., N'Da G., Lorenzoni C., Liu B., Kantelhardt E.J., Parkin D.M.: (2020) Rising Prostate Cancer Incidence in Sub-Saharan

Africa: A Trend Analysis of Data from the African Cancer Registry Network. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, Epub: Epub [33033143](#)

IF: 4,344; anteiliger IF: 0,10339

23. Swain S.M., Miles D., Kim S.B., Im Y.H., Im S.A., Semiglazov V., Ciruelos E., Schneeweiss A., Loi S., Monturus E., Clark E., Knott A., Restuccia E., Benyunes M.C., Cortés J., CLEOPATRA study group: (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. LANCET ONCOLOGY, 21: 519-530 [32171426](#)
IF: 33,752; anteiliger IF: 0,00675
24. Teka B., Gizaw M., Ruddies F., Addissie A., Chanyalew Z., Skof A.S., Thies S., Mihret A., Kantelhardt E.J., Kaufmann A.M., Abebe T.: (2020) Population-based human papillomavirus infection and genotype distribution among women in rural areas of South Central Ethiopia. INTERNATIONAL JOURNAL OF CANCER, XXX: XXX-XXX [32875552](#)
IF: 5,145; anteiliger IF: 0,19037
25. Thomssen C., Lüftner D., Untch M., Haidinger R., Würstlein R., Harbeck N., Augustin D., Briest S., Ettl J., Fasching P.A., Förster F., Kurbacher C.M., Lück H.J., Marschner N., Müller L., Müller V., Perlova-Griff L., Radke I., Ruckhäberle E., Scheffen I., Schumacher-Wulf E., Schwoerer M., Steinfeld-Birg D., Ziegler-Löhr K.: (2020) International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts. BREAST CARE, 15: 82-95 [32231503](#)
IF: 2,029; anteiliger IF: 0,67627
26. Untch M., Würstlein R., Lüftner D., Haidinger R., Fasching P.A., Augustin D., Briest S., Ettl J., Förster F., Kurbacher C.M., Lück H.J., Marschner N., Müller L., Müller V., Radke I., Ruckhäberle E., Scheffen I., Schumacher-Wulf E., Schwoerer M., Steinfeld-Birg D., Ziegler-Löhr K., Thomssen C., Harbeck N.: (2020) ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results. GEBURTSHILFE UND FRAUENHEILKUNDE, 80: 588-600 [32565549](#)
IF: 2,382; anteiliger IF: 0,03787
27. Ziegenhorn H.V., Frie K.G., Ekanem I.O., Ebughe G., Kamate B., Traore C., Dзамalala C., Ogunbiyi O., Igbinoba F., Liu B., Bauer M., Thomssen C., Parkin D.M., Wickenhauser C., Kantelhardt E.J.: (2020) Breast cancer pathology services in sub-Saharan Africa: a survey within population-based cancer registries. BMC HEALTH SERVICES RESEARCH, 20: 912 [33008380](#)
IF: 1,99; anteiliger IF: 0,71421

2020 Summe der Bewertungen: 19,43066, Summe IF = 210.4